Literature DB >> 20227126

Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation.

Michael P Greenbaum1, Eric A Strom, Pamela K Allen, George H Perkins, Julia L Oh, Welela Tereffe, Tse-Kuan Yu, Thomas A Buchholz, Wendy A Woodward.   

Abstract

PURPOSE: To determine the rate of locoregional recurrence (LRR) associated with modern tri-modality therapy.
METHODS: We retrospectively reviewed data from 291 consecutive PMRT patients treated from 1999 to 2001. These patients were compared to an historical group of 313 patients treated from 1979 to 1988 who had fluoroscopic simulation and contour-generated 2D planning. 1999-2001 spans the adoption of CT simulators for breast radiation therapy and a comparison was made between patients simulated before and after the implementation of CT simulation. Five-year actuarial rates for LRR, distal metastasis (DM), and overall survival (OS) between the pre and post CT simulation cohorts were compared as well.
RESULTS: Compared to a 2D planned historic control, the combined contemporary patients had improved outcomes at 5years for all endpoints studied; LRR 3.0% vs. 11.5%, DM 29.2% vs. 39.2%, and OS 79.2% vs. 70.6% (p=0.0004, 0.0052, 0.0012, respectively). Significant factors in a multivariate analysis for LRR were: advanced T-stage (RR=2.14, CI=1.11-4.11, p=0.023), and percent positive nodes (RR=1.01, CI=1.00-1.02, p=0.012). The comparison of the pre and post CT-simulated PMRT patients (1999-2001) found no significant difference in any endpoint.
CONCLUSIONS: The rate of locoregional control for PMRT patients treated with modern radiotherapy is outstanding and has improved significantly compared to historical controls. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227126      PMCID: PMC3063386          DOI: 10.1016/j.radonc.2010.02.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  21 in total

1.  Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute.

Authors:  A U Buzdar; G N Hortobagyi; C E Marcus; T L Smith; R Martin; E A Gehan
Journal:  NCI Monogr       Date:  1986

2.  The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization.

Authors: 
Journal:  Am J Clin Pathol       Date:  1982-12       Impact factor: 2.493

3.  A custom three-dimensional electron bolus technique for optimization of postmastectomy irradiation.

Authors:  G H Perkins; M D McNeese; J A Antolak; T A Buchholz; E A Strom; K R Hogstrom
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-15       Impact factor: 7.038

4.  Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.

Authors:  A U Buzdar; G N Hortobagyi; T L Smith; S Kau; C Marcus; F A Holmes; V Hug; G Fraschini; F C Ames; R G Martin
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

5.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

Authors:  A R Feinstein; D M Sosin; C K Wells
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

6.  Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial.

Authors:  A U Buzdar; G R Blumenschein; T L Smith; K C Powell; G N Hortobagyi; H Y Yap; F C Schell; B C Barnes; F C Ames; R G Martin
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

7.  Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival.

Authors:  Wendy A Woodward; Eric A Strom; Susan L Tucker; Marsha D McNeese; George H Perkins; Naomi R Schechter; S Eva Singletary; Richard L Theriault; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

8.  Combined modality approach in breast cancer with isolated or multiple metastases.

Authors:  A U Buzdar; G R Blumenschein; E D Montague; G N Hortobagyi; H Y Yap; K Pinnamaneni; C E Marcus; T L Smith
Journal:  Am J Clin Oncol       Date:  1984-02       Impact factor: 2.339

9.  Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.

Authors:  Wendy A Woodward; Eric A Strom; Susan L Tucker; Angela Katz; Marsha D McNeese; George H Perkins; Aman U Buzdar; Gabriel N Hortobagyi; Kelly K Hunt; Aysegul Sahin; Funda Meric; Nour Sneige; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-10-01       Impact factor: 7.038

10.  The use of computed tomography in radiotherapy treatment planning for breast cancer. How does conventional radiotherapy planning compare with virtual?

Authors:  O Bauduceau; M A Bollet; P Pons; Y M Kirova; M Fayolle; S Zervoudis; F Campana
Journal:  J BUON       Date:  2008 Apr-Jun       Impact factor: 2.533

View more
  7 in total

Review 1.  Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment.

Authors:  Savitri Krishnamurthy; Therese Bevers; Henry M Kuerer; Benjamin Smith; Wei Tse Yang
Journal:  AJR Am J Roentgenol       Date:  2016-12-08       Impact factor: 3.959

2.  Postmastectomy radiation therapy for inflammatory breast cancer: is more better?

Authors:  Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

3.  Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation.

Authors:  Vinita Takiar; Catherine L Akay; Michael C Stauder; Welela Tereffe; Ricardo H Alvarez; Karen E Hoffman; George H Perkins; Eric A Strom; Thomas A Buchholz; Naoto T Ueno; Gildy Babiera; Wendy A Woodward
Journal:  Springerplus       Date:  2014-03-31

4.  An Innovative Risk-Reducing Approach to Postmastectomy Radiation Delivery after Autologous Breast Reconstruction.

Authors:  Merisa L Piper; Maristella Evangelista; Dominic Amara; David Daar; Robert D Foster; Barbara Fowble; Hani Sbitany
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-04-25

5.  Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer.

Authors:  Ying Lu; Haixin Huang; Hui Yang; Dagui Chen
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817

6.  Postmastectomy radiation therapy can improve survival for breast cancer patients with 1-3 positive axillary lymph nodes: a retrospective cohort study using the SEER database.

Authors:  Jian Yang; Xiao Zhang; Yifeng Ye; Yunyan Lin; Qingmo Yang; Haoyang Cai
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

7.  Whether adjuvant radiotherapy is desired for postmastectomy patients with T1-T2 tumors and 1-3 positive axillary lymph nodes who received modern systemic therapy?

Authors:  Shih-Fan Lai; Chiun-Sheng Huang; Sung-Hsin Kuo
Journal:  Transl Cancer Res       Date:  2019-03       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.